/
Cardiovascular
Atherosclerosis
37
Pipeline Programs↗
44
Active Trials↗
27
Companies Involved↗
Atherosclerosis is a moderately active landscape with 37 programs across 27 companies. The most active players are Novo Nordisk, Atom Therapeutics Co., Ltd, Amryt Pharma. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical28
Phase 1
No programs
Phase 23
Phase 36
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
33 of 37 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 37 pipeline programs.
Analysis
Trial Status
198
clinical trials
Completed96 · 48%
Unknown status31 · 16%
Recruiting25 · 13%
Terminated15 · 8%
Not yet recruiting14 · 7%
Withdrawn11 · 6%
Other6 · 3%
Clinical Trials
Trial Activity
198 trials
The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
Recruiting·—·Phase 4·NCT06757764·2,340 enrolled
Page 1 of 14
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)